key: cord-0819240-m7nl8v93 authors: Bornemann, Linus; Kaup, Olaf; Kleideiter, Johannes; Panning, Marcus; Ruprecht, Bertram; Wehmeier, Michael title: Real-life evaluation of the Sofia SARS-CoV-2 antigen assay in a large tertiary care hospital date: 2021-05-10 journal: J Clin Virol DOI: 10.1016/j.jcv.2021.104854 sha: 53826c6b9735d3bccaddf60469649401e80784a5 doc_id: 819240 cord_uid: m7nl8v93 nan Email: marcus.panning@uniklinik-freiburg.de Highlights:  We evaluated the Sofia rapid antigen test (RAT) in a real-life setting.  At total of 1,404 patients were prospectively enrolled.  Clinical sensitivity in comparison to nucleic acid detection testing (NAT) was 57%.  Detection rates of RAT improved to 95% in NAT positive samples with Ct values ≤ 25.  The Sofia RAT might assist in on-site testing to rapidly detect infectious patients. Keywords: SARS-CoV-2, Point of care testing, rapid antigen detection, Sofia antigen SARS-CoV-2 assay, Nucleic acid testing, Real-life comparison To the Editor, Rapid and reliable detection of SARS-CoV-2 is instrumental to control and ultimately contain the COVID-19 pandemic. Nucleic acid based testing (NAT) remains the gold standard for SARS-CoV-2 detection [1] . However, NAT is usually restricted to diagnostic laboratories with specialized equipment and professional personnel. This limits their application for point of care testing (POCT). Recently, rapid antigen tests (RAT) entered the market for POCT use and proved their principle in different studies [2] [3] [4] . We aimed to evaluate the clinical performance of the Sofia antigen test in comparison to SARS-CoV-2 NAT in a real-life setting in a large tertiary care center. We prospectively enrolled all patients admitted to the emergency department at Bielefeld Hospital, a tertiary care hospital with 1,300 beds in northern Germany from 1 November to 30 November 2020. Trained medical personnel took two nasopharyngeal swab samples per patient. One sample was immediately tested on site using the Sofia antigen fluorescent Nine samples showed a positive antigen FIA result, but were negative using NAT (8 of the 9 patients were re-tested with NAT within 2 days and remained NAT negative, one was not retested). This indicates a specificity of 99.3%. Thirteen (0.9%) antigen FIA showed invalid results. Of note, this low rate compares very well to previous findings [5] . Positive and negative predictive value and diagnostic test accuracy were 85.2%, 97.1% and 96.5%, respectively. The mean Ct value in concordant NAT/antigen FIA positive samples was significantly lower than in discordant NAT positive/antigen FIA negative samples ( Figure 1 ). [4, 6] . Technically, the FIA analyzer allows userindependent interpretation of test results and electronic connectivity to the laboratoryinformation system, which also facilitates documentation of test results. However, the use of technical equipment is associated with slightly higher costs including e.g. maintenance. Our findings support the notion that RAT are able to identify infectious patients, who can potentially transmit virus to others. Importantly, their applicability for POCT and inexpensiveness may prove beneficial for frequent on-site testing in settings beyond hospitals like long-term care facilities and schools. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected anterior nasal swab versus professional-collected nasopharyngeal swab Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread? Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses -Wisconsin We kindly acknowledge expert literature search by Alexey Fomenko. This work was in part supported by the German Federal Ministry of Education and Research (CEO-sys; TF-1/Z24; Fkz. 01KX2021) The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors report no conflict of interest.